On thursday 28 February 2008 the Dutch Parliamentary Justice Commission devoted its debate to the drugs UNGASS review. Martin Jelsma was invited as one of the experts to share with the commission TNI's views on the importance of the review process. In his contribution he highlights the opportunity to use the 2008/9 period to achieve a breakthrough on harm reduction acceptance at the UN level, to evaluate the performance of UN agencies like UNODC and the INCB, and to open the door for a revision of the UN drug control treaty system. only available in Dutch
Peter Reuter (RAND), Franz Trautmann (Trimbos Institute) (eds.)
15 March 2009
This report commissioned by the European Commission, found no evidence that the global drug problem has been reduced during the period from 1998 to 2007 – the primary target of the 1998 UNGASS, which aimed to significantly reduce the global illicit drugs problem by 2008 through international cooperation and measures in the field of drug supply and drug demand reduction. Broadly speaking the situation has improved a little in some of the richer countries, while for others it worsened, and for some of those it worsened sharply and substantially', among which are a few large developing or transitional countries. Given the limitations of the data, a fair judgment is that the problem became somewhat more severe.
The last of the four ‘round tables’ of the high-level segment of the Commission on Narcotic Drugs was devoted to the broad issue of Countering illicit drug traffic and supply, and alternative development. TNI had been nominated by the Vienna NGO Committee to give a statement on the issue of Alternative Development (AD), being one of the few member NGOs with a track record on this issue and having actively participated in the Beyond 2008 initiative, including the negotiations at the July NGO forum to reach consensus on the text of a paragraph on AD in the final declaration. This is our impression of the event.
This study brings together available evidence to provide a comprehensive analysis of cannabis production and markets across the EU. It combines information from EMCDDA routine reporting — data on patterns of prevalence and use, seizures, police reports, drug-law offences, cannabis potency and retail market prices — with literature on cannabis markets to create an in-depth analysis of the issue in a European context.